Website review medincell.com
Medincell - Impacting Global Health with Purposeful Innovation
Generated on May 04 2026 08:46 AM
Old data? UPDATE !
The score is 54/100
SEO Content
Title
Medincell - Impacting Global Health with Purposeful Innovation
Length : 62
Perfect, your title contains between 10 and 70 characters.
Description
MedinCell creates better medicine for all through innovative long‑acting therapies that help improve global health.
Length : 115
Great, your meta description contains between 70 and 160 characters.
Keywords
Very bad. We haven't found meta keywords on your page. Use this free online meta tags generator to create keywords.
Og Meta Properties
Good, your page take advantage of Og Properties.
| Property | Content |
|---|---|
| url | https://www.medincell.com/ |
| site_name | Medincell |
| locale | en_US |
| locale:alternate | fr_FR |
| type | website |
| title | Medincell - Impacting Global Health with Purposeful Innovation |
| description | Join Medincell on a journey to transform global health with innovative therapies. |
| image | https://www.medincell.com/wp-content/uploads/2026/02/Open_graph.jpg |
| image:secure_url | https://www.medincell.com/wp-content/uploads/2026/02/Open_graph.jpg |
| image:width | 1640 |
| image:height | 856 |
| image:alt | Logo de Medincell en bleu |
Headings
| H1 | H2 | H3 | H4 | H5 | H6 |
| 1 | 9 | 5 | 25 | 0 | 0 |
- [H1] Impacting Global Health with Purposeful Innovation
- [H2] Latest news & events
- [H2] Improving health worldwide through new therapeutic options
- [H2] Key figures
- [H2] Products & R&D pipeline
- [H2] mdc-TJK
- [H2] mdc-CWM
- [H2] Join the team
- [H2] Corporate presentation
- [H2] Get in touch
- [H3] Products on market
- [H3] UZEDY®
- [H3] Programs in clinical phase 3
- [H3] mdc-TJK
- [H3] mdc-CWM
- [H4] UZEDY®: Q1 2026 Net Sales Reached $63M, Up 62% Year‑on‑Year
- [H4] Degroof Petercam Initiates Medincell’s Coverage with a “Buy” Recommendation
- [H4] Leerink Partners Initiates Medincell’s Coverage with a “Outperform” Recommendation
- [H4] Medincell to Host an online R&D Day on Tuesday, May 12, 2026
- [H4] 1
- [H4] 2
- [H4] 140
- [H4] 25
- [H4] U.S. Food and Drug Administration (FDA) Accepts Teva’s New Drug Application (NDA) for Olanzapine Extended-Release Injectable Suspension (TEV-‘749) for the Once-Monthly Treatment of Schizophrenia in Adults
- [H4] UZEDY®: Net Sales Increased from $117M in 2024 to $191M in 2025 (+63%) ; OLANZAPINE LAI: EU Submission Expected in Q2 2026
- [H4] Medincell’s Partner Teva Pharmaceuticals Announces the New Drug Application Submission to U.S. FDA for Olanzapine Extended-Release Injectable Suspension (TEV-‘749 / mdc-TJK) for the Once-Monthly Treatment of Schizophrenia in Adults
- [H4] UZEDY® continues strong growth; Teva setting the stage for US NDA Submission for Olanzapine LAI in Q4 2025
- [H4] New Pivotal Phase 3 Long-Term Data Supports Olanzapine Long-Acting Injectable (LAI) with Favorable Safety Profile – No PDSS Observed
- [H4] Teva to Host Investor Call on Completed Phase 3 Olanzapine LAI Data Following Psych Congress 2025 Presentation
- [H4] UZEDY® Accelerates: 2025 Revenue Outlook Raised to $190–$200M (from ~$160M); Olanzapine LAI on Track for Submission in 2025
- [H4] UZEDY® Continues Strong Momentum in 2025; Olanzapine LAI on Track for FDA Filing in H2 2025
- [H4] Phase 3 Survey Results Demonstrate Patient and Healthcare Professional Satisfaction with Olanzapine LAI
- [H4] Completion of the Pivotal Phase 3 Trial for Olanzapine LAI in Schizophrenia
- [H4] Medincell and AIC Unveil New Positive Phase 3 Results for mdc-CWM
- [H4] Medincell Provides Update on Phase 3 mdc-CWM Clinical Trial
- [H4] MedinCell announces successful completion of patient enrollment in the Phase 3 study of F14 (mdc-CWM), a first-in-class therapy for localized pain relief after Total knee replacement
- [H4] MedinCell announces the initiation of Phase 3 study of F14 (mdc-CWM), a therapeutic first-in-class that aims to provide weeks of localized pain relief after Total Knee Replacement
- [H4] MedinCell: mdc-CWM clinical phase 3 will start in 2021
- [H4] MedinCell provides a portfolio update for J.P. Morgan Healthcare Conference 2020
- [H4] MedinCell announces that mdc-CWM progresses as planned
Images
We found 8 images on this web page.
4 alt attributes are empty or missing. Add alternative text so that search engines can better understand the content of your images.
Text/HTML Ratio
Ratio : 1%
This page's ratio of text to HTML code is below 15 percent, this means that your website probably needs more text content.
Flash
Perfect, no Flash content has been detected on this page.
Iframe
Too Bad, you have Iframes on the web pages, this mean that content in an Iframe cannot be indexed.
SEO Links
URL Rewrite
Good. Your links looks friendly!
Underscores in the URLs
Perfect! No underscores detected in your URLs.
In-page links
We found a total of 30 links including 1 link(s) to files
| Anchor | Type | Juice |
|---|---|---|
| Skip to main content | Internal | Passing Juice |
| Access Event | Internal | Passing Juice |
| Home | Internal | Passing Juice |
| See our R&D pipeline | Internal | Passing Juice |
| - | Internal | Passing Juice |
| See our open positions | Internal | Passing Juice |
| I have read and accept the privacy policy | Internal | Passing Juice |
| - | External | Passing Juice |
| - | External | Passing Juice |
| - | External | Passing Juice |
| Home | Internal | Passing Juice |
| About Us | Internal | Passing Juice |
| Impact company | Internal | Passing Juice |
| Our people | Internal | Passing Juice |
| Leadership team | Internal | Passing Juice |
| UZEDY® | Internal | Passing Juice |
| R&D Pipeline | Internal | Passing Juice |
| BEPO® Technology | Internal | Passing Juice |
| Publications | Internal | Passing Juice |
| Our commitments | Internal | Passing Juice |
| Code and policies | Internal | Passing Juice |
| 2025 ESG Report | Internal | Passing Juice |
| Our vision & our values | Internal | Passing Juice |
| Work environment & benefits | Internal | Passing Juice |
| News | Internal | Passing Juice |
| Events | Internal | Passing Juice |
| Overview | Internal | Passing Juice |
| Regulated information | Internal | Passing Juice |
| General Meeting | Internal | Passing Juice |
| Contact | Internal | Passing Juice |
SEO Keywords
Keywords Cloud
environment events benefits medincell information search news team values vision
Keywords Consistency
| Keyword | Content | Title | Keywords | Description | Headings |
|---|---|---|---|---|---|
| news | 4 |  |
|
|
 |
| information | 4 | |
|
|
|
| events | 4 | |
|
|
|
| medincell | 3 | |
|
|
|
| vision | 3 | |
|
|
|
Usability
Url
Domain : medincell.com
Length : 13
Favicon
Great, your website has a favicon.
Printability
We could not find a Print-Friendly CSS.
Language
Good. Your declared language is en.
Dublin Core
Great. This page take advantage of Dublin Core.
Document
Doctype
HTML 5
Encoding
Perfect. Your declared charset is UTF-8.
W3C Validity
Errors : 0
Warnings : 0
Email Privacy
Great no email address has been found in plain text!
Deprecated HTML
Great! We haven't found deprecated HTML tags in your HTML.
Speed Tips
|
Excellent, your website doesn't use nested tables. |
|
Too bad, your website is using inline styles. |
|
Too bad, your website has too many CSS files (more than 4). |
|
Too bad, your website has too many JS files (more than 6). |
|
Perfect, your website takes advantage of gzip. |
Mobile
Mobile Optimization
|
Apple Icon |
|
Meta Viewport Tag |
|
Flash content |
Optimization
XML Sitemap
Great, your website has an XML sitemap.
| https://www.medincell.com/sitemaps.xml |
Robots.txt
https://medincell.com/robots.txt
Great, your website has a robots.txt file.
Analytics
Missing
We didn't detect an analytics tool installed on this website.
Web analytics let you measure visitor activity on your website. You should have at least one analytics tool installed, but It can also be good to install a second in order to cross-check the data.
PageSpeed Insights
Device
Categories
Free SEO Testing Tool
Free SEO Testing Tool is a free SEO tool which provides you content analysis of the website.